Proposed placing of unlisted warrants under Specific mandate
Filed with HKEX · Stock code 3378 · · 17 pages · English
Summary by 6ix AI
Hanx Biopharmaceuticals (Wuhan) Co. Ltd. has announced a proposed placing of unlisted warrants under a specific mandate to raise funds for general working capital and clinical research for new products. The completion of this placing is contingent upon certain conditions being met, including shareholder approval and regulatory permissions. The company will not seek a listing for the warrants themselves but will apply for the listing of the shares issued upon their exercise.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Hanx Biopharmaceuticals (Wuhan) Co. Ltd. on 6ix
Earlier from Hanx Biopharmaceuticals (Wuhan)
- Next Day Disclosure Return
- Voluntary announcement notice on voluntary extension of lock-up period by shareholders
- Voluntary announcement inclusion of Hanx Biopharmaceuticals in the FTSE global micro cap index
Later from Hanx Biopharmaceuticals (Wuhan)
- 2026 Interim report
- Voluntary announcement entering into strategic cooperation with xtalpi
- Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 September 2026
Follow Hanx Biopharmaceuticals (Wuhan) into a list and get an email when it puts out news.
Follow Hanx Biopharmaceuticals (Wuhan)